Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IARS1 | P41252 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857059 | 0.93 | KDM4E (0.44) | KDM4ESLC22A6SLC22A8HSD17B2POLB | |
| SCHEMBL2860150 | 0.91 | KDM4E (0.46) | KDM4ESLC22A6SLC22A8HSD17B2POLB | |
| SCHEMBL2866300 | 0.90 | KDM4E (0.38) | KDM4EHSD17B2POLBPTPN1CYP1A2 | |
| SCHEMBL2858288 | 0.89 | FLT3 (0.43) | KDM4EPOLBPTPN1HSP90AA1RAB9A | |
| SCHEMBL2861148 | 0.89 | KDM4E (0.40) | KDM4EPOLBPTPN1RAB9ANPC1 | |
| SCHEMBL2857454 | 0.89 | KDM4E (0.43) | KDM4EPOLBPTPN1RAB9ANPC1 | |
| SCHEMBL2866511 | 0.88 | KDM4E (0.48) | KDM4EPOLBRAB9ANPC1MAPT | |
| SCHEMBL2861264 | 0.88 | KDM4E (0.48) | KDM4EPOLBRAB9ANPC1MAPT | |
| SCHEMBL2859390 | 0.88 | KDM4E (0.44) | KDM4EPOLBCYP1A2RAB9AHDAC6 | |
| SCHEMBL2856154 | 0.88 | KDM4E (0.44) | KDM4EPOLBCYP1A2RAB9AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | KDM4E 2968/4885SLC22A6 1282/4885SLC22A8 1843/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | KDM4E 2968/4885SLC22A6 1282/4885SLC22A8 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.